Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2025-12-26 @ 12:01 AM
Study NCT ID:
NCT04572594
Status:
UNKNOWN
Last Update Posted:
2020-10-01
First Post:
2020-09-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Molecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic Tumor
Sponsor:
Sun Yat-sen University
Organization:
Study Overview
Official Title:
Study on the Molecular Profile and Molecular Signature of Inflammatory Myofibroblastic Tumor
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gene mutation is a research hotspot in the occurrence of multiple malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of genes related to inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.
Detailed Description:
Inflammatory myofibroblastic tumor（IMT）is a rare clinical mesenchymal tissue-derived tumor, which can occur in almost all organs and soft tissues, and is characterized by low-grade or borderline tumors.
The diagnosis of inflammatory myofibroblastic tumor is mainly based on histopathology and immunohistochemistry. The treatment is resistant to conventional chemotherapy and radiotherapy. The only curative treatment is complete surgical resection. When IMT shows typical cellular structural features in pathology, the diagnosis is relatively simple. However, in the presence of atypical features, the accurate diagnosis of IMT is still a challenge. Therefore, it is necessary to explore a better diagnostic method. Secondly, there is no individualized treatment method for aggressive IMT patients who relapse and metastasize after surgery. At present, gene mutation is a research hotspot in the occurrence of various malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.
The diagnosis of inflammatory myofibroblastic tumor is mainly based on histopathology and immunohistochemistry. The treatment is resistant to conventional chemotherapy and radiotherapy. The only curative treatment is complete surgical resection. When IMT shows typical cellular structural features in pathology, the diagnosis is relatively simple. However, in the presence of atypical features, the accurate diagnosis of IMT is still a challenge. Therefore, it is necessary to explore a better diagnostic method. Secondly, there is no individualized treatment method for aggressive IMT patients who relapse and metastasize after surgery. At present, gene mutation is a research hotspot in the occurrence of various malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: